Jeena Sikho

Why is Jeena Sikho Lifecare Ltd falling/rising?

As of 09-Aug, Jeena Sikho Lifecare Ltd's stock price is declining to Rs 597.05, down 1.2% after two days of gains, influenced by reduced institutional investor participation and a high price-to-book value ratio. Despite some positive financial indicators, the stock's year-to-date performance is down 12.28%, indicating potential overvaluation and lack of confidence among investors.

As of 09-Aug, Jeena Sikho Lifecare Ltd's stock price is falling, currently at Rs 597.05, which reflects a decrease of Rs 7.25 or 1.2%. This decline follows a trend reversal after two consecutive days of gains. The stock has underperformed its sector by 1.34% today and reached an intraday low of Rs 590.15, marking a drop of 2.34%. <BR><BR>Despite some positive indicators, such as a strong ability to service debt and healthy long-term growth in net sales and operating profit, the stock's performance has been negatively impacted by a decrease in institutional investor participation, which has fallen by 1.48% over the previous quarter. This decline in institutional interest may signal a lack of confidence among more sophisticated investors, contributing to the stock's downward movement. <BR><BR>Additionally, while the stock has shown positive returns over the past week and month, its year-to-date performance is down by 12.28%, which contrasts with the Sensex's decline of 7.89% in the same period. The current valuation metrics, including a high price-to-book value ratio, further suggest that the stock may be perceived as expensive, leading to selling pressure. Overall, these factors collectively explain the current fall in Jeena Sikho Lifecare Ltd's stock price.

Which are the latest news on Jeena Sikho?

Should I buy, sell or hold Jeena Sikho Lifecare Ltd?

When is the next results date for Jeena Sikho Lifecare Ltd?

The next results date for Jeena Sikho Lifecare Ltd is 07 August 2026.

The next results date for Jeena Sikho Lifecare Ltd is scheduled for 07 August 2026.

What does Jeena Sikho do?

Jeena Sikho Lifecare Ltd is a small-cap Ayurvedic healthcare company, incorporated in 2017 and converted to a public company in 2021, with net sales of 216 Cr and a net profit of 45 Cr as of March 2026. Key metrics include a P/E ratio of 33.00 and a market cap of INR 7,408 Cr.

Overview: <BR>Jeena Sikho Lifecare Ltd is an Ayurvedic healthcare company operating in the hospital industry and classified as a small-cap entity.<BR><BR>History: <BR>Jeena Sikho Lifecare Ltd was originally incorporated in 2017 as a Private Limited Company and later converted to a Public Limited Company in 2021. The latest quarterly results report net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 216 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 45 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 7,408 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 33.00 <BR>Industry P/E: 60 <BR>Dividend Yield: 0.18% <BR>Debt-Equity: -0.16 <BR>Return on Equity: 47.54% <BR>Price to Book: 16.17<BR><BR>Contact Details: <BR>Registrar Address: Not available. <BR>Phone: N/A <BR>Email: N/A <BR>Website: N/A

How big is Jeena Sikho?

As of 10th June, Jeena Sikho Lifecare Ltd has a market capitalization of 7,408.00 Cr, with recent Net Sales of 801.37 Cr and a Net Profit of 221.81 Cr. The company reported Shareholder's Funds of 125.80 Cr and Total Assets of 150.59 Cr for the year ending March 2023.

As of 10th June, Jeena Sikho Lifecare Ltd has a market capitalization of 7,408.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, Jeena Sikho reported Net Sales of 801.37 Cr and a Net Profit of 221.81 Cr.<BR><BR>For the latest annual period ending in March 2023, the company had Shareholder's Funds of 125.80 Cr and Total Assets amounting to 150.59 Cr.

Who are in the management team of Jeena Sikho?

The management team of Jeena Sikho includes Manish Grover (Executive Director, INR 2.4 crores), Bhavna Grover (Whole-time Director, INR 1.8 crores), Shreya Grover (Non-Executive Director, no remuneration), Suraj Prakash Choudhary (Non-Executive Director, INR 1.44 lakhs), Karan Vir Bindra (Non-Executive Director, INR 1.44 lakhs), and Nikita Juneja (Company Secretary & Compliance Officer, INR 3.0 lakhs). They are responsible for the company's strategic direction and regulatory compliance.

The management team of Jeena Sikho includes the following members:<BR><BR>1. **Manish Grover** - Executive Director, with a remuneration of INR 2.4 crores.<BR>2. **Bhavna Grover** - Whole-time Director, with a remuneration of INR 1.8 crores.<BR>3. **Shreya Grover** - Non-Executive Director, with no remuneration.<BR>4. **Suraj Prakash Choudhary** - Non-Executive Director, with a remuneration of INR 1.44 lakhs.<BR>5. **Karan Vir Bindra** - Non-Executive Director, also with a remuneration of INR 1.44 lakhs.<BR>6. **Nikita Juneja** - Company Secretary & Compliance Officer, with a remuneration of INR 3.0 lakhs.<BR><BR>This team is responsible for guiding the company's strategic direction and ensuring compliance with regulations.

Who are the peers of the Jeena Sikho?

Jeena Sikho's peers include Rainbow Child, Health.Global, Jupiter Life Lin, Yatharth Hospital, Kovai Medical, Artemis Medicare, Indrapr.Medical, Dr. Agarwal's Eye, and KMC Speciality. In terms of management risk, growth, and capital structure, they vary from excellent to below average, with KMC Speciality showing the highest 1-year return at 74.95%.

Peers: The peers of Jeena Sikho are Rainbow Child., Health.Global, Jupiter Life Lin, Yatharth Hospit., Kovai Medical, Artemis Medicare, Indrapr.Medical, Dr Agarwal's Eye, and KMC Speciality.<BR><BR>Quality Snapshot: Excellent management risk is observed at Rainbow Child., Jupiter Life Lin, and Kovai Medical, while Average management risk is found at Health.Global, Artemis Medicare, Indrapr.Medical, Dr Agarwal's Eye, and KMC Speciality, and Below Average management risk is noted at Yatharth Hospit. In terms of growth, Excellent growth is seen at Health.Global, Jeena Sikho, Yatharth Hospit., and KMC Speciality, while Good growth is noted at Rainbow Child., Jupiter Life Lin, Artemis Medicare, Indrapr.Medical, and the rest. Below Average growth is present at Kovai Medical, and Below Average growth is also observed at Yatharth Hospit. Capital Structure ratings show Excellent at Jupiter Life Lin, Jeena Sikho, Yatharth Hospit., Indrapr.Medical, and KMC Speciality, while Good is noted at Rainbow Child. and Kovai Medical, and Average is found at Dr Agarwal's Eye.<BR><BR>Return Snapshot: KMC Speciality has the highest 1-year return at 74.95%, while Jupiter Life Lin has the lowest at -13.75%. Jeena Sikho's 1-year return is not available for comparison. Additionally, the peers with negative six-month returns include Health.Global, Indrapr.Medical, and Artemis Medicare.

Are Jeena Sikho Lifecare Ltd latest results good or bad?

Jeena Sikho Lifecare Ltd's latest results show strong year-on-year growth, with a 78.10% increase in net profit and a 54.79% rise in revenue. However, quarterly performance is concerning, with declines in both net profit and revenue, along with reduced profit margins, indicating potential challenges ahead.

The latest results for Jeena Sikho Lifecare Ltd present a mixed picture. On one hand, the company reported a significant year-on-year growth, with net profit increasing by 78.10% to ₹45.13 crore and revenue rising by 54.79% to ₹215.55 crore. This indicates strong annual performance and robust sales growth.<BR><BR>However, the quarterly results show concerning trends. Compared to the previous quarter, both net profit and revenue declined, with net profit falling by 32.30% and revenue decreasing by 2.77%. Additionally, the profit after tax margin dropped sharply from 30.04% to 20.91%, reflecting rising operational pressures. The operating margin also contracted significantly, indicating potential challenges in maintaining profitability.<BR><BR>Overall, while the company demonstrates strong long-term growth potential and exceptional return on equity, the recent quarterly performance raises questions about sustainability and could be seen as a warning sign for investors. Thus, the results can be characterized as good in terms of year-on-year growth, but bad when considering the sequential decline and margin compression.

Is Jeena Sikho technically bullish or bearish?

As of November 25, 2025, Jeena Sikho's trend has shifted to sideways, indicating a neutral stance with mixed signals from key indicators, including a mildly bearish outlook from Dow Theory and a mildly bullish trend in On-Balance Volume.

As of 25 November 2025, the technical trend for Jeena Sikho has changed from mildly bearish to sideways. The current stance is neutral, reflecting a lack of strong directional movement. Key indicators include a mildly bearish outlook from Dow Theory on the weekly timeframe, while the On-Balance Volume (OBV) shows a mildly bullish trend on the weekly basis. The MACD, RSI, and other indicators do not provide clear signals at this time. Overall, the stock's recent performance shows a slight gain over the past week, contrasting with a decline over the past month.

How has been the historical performance of Jeena Sikho?

Jeena Sikho experienced significant growth from March 2022 to March 2023, with net sales increasing to 204.75 Cr from 146.55 Cr, and profit after tax rising to 33.52 Cr from 11.19 Cr, reflecting strong improvements in operating profit margins and overall financial performance. Total assets also grew to 150.59 Cr, while cash flow showed a positive turnaround.

Answer:<BR>The historical performance of Jeena Sikho shows significant growth in various financial metrics from March 2022 to March 2023.<BR><BR>Breakdown:<BR>In the fiscal year ending March 2023, Jeena Sikho reported net sales of 204.75 Cr, a notable increase from 146.55 Cr in the previous year. Total operating income mirrored this growth, reaching 204.75 Cr compared to 146.55 Cr in March 2022. The total expenditure, excluding depreciation, rose to 159.15 Cr from 128.50 Cr, while operating profit (PBDIT) surged to 48.20 Cr from 19.54 Cr, indicating a robust operating profit margin improvement from 12.32% to 22.27%. Profit before tax also saw a substantial rise to 44.29 Cr from 15.09 Cr, leading to a profit after tax of 33.52 Cr, up from 11.19 Cr, resulting in a PAT margin increase from 7.64% to 16.37%. The company's total assets grew to 150.59 Cr from 61.54 Cr, with total liabilities increasing to 150.59 Cr from 61.54 Cr. Cash flow from operating activities decreased slightly to 14.00 Cr from 16.00 Cr, but net cash inflow improved significantly to 29.00 Cr from a net outflow of 6.00 Cr, reflecting a strong closing cash position of 31.00 Cr compared to 2.00 Cr the previous year. Overall, Jeena Sikho demonstrated a strong upward trend in financial performance across key metrics.

Who are the top shareholders of the Jeena Sikho?

The top shareholders of Jeena Sikho include Manish Grover with 63.27%, Oregano Life Private Limited at 5.8%, and 12 foreign institutional investors holding a combined 5.91%. Individual investors own 17.05%, with no pledged promoter holdings or mutual fund investments.

The top shareholders of Jeena Sikho include the promoters, with Manish Grover holding the highest share at 63.27%. Additionally, Oregano Life Private Limited is the largest public shareholder, owning 5.8%. The company also has 12 foreign institutional investors (FIIs) that collectively hold 5.91% of the shares, while individual investors account for 17.05% of the holdings. There are no pledged promoter holdings, and no mutual funds currently hold shares in the company.

Is Jeena Sikho overvalued or undervalued?

As of May 19, 2025, Jeena Sikho is considered very expensive with a PE ratio of 61.03 and high valuation metrics, despite outperforming the Sensex with a 102.02% return over the past year, indicating it is overvalued compared to industry norms and some competitors.

As of 19 May 2025, the valuation grade for Jeena Sikho has moved from does not qualify to very expensive, indicating a significant shift in its perceived value. The company is currently overvalued, with a PE ratio of 61.03, a Price to Book Value of 28.80, and an EV to EBITDA ratio of 43.82, all of which are considerably high compared to industry norms. <BR><BR>In comparison to its peers, Max Healthcare Institute Ltd. has a PE ratio of 100.29 and an EV to EBITDA of 62.71, while Apollo Hospitals Enterprise Ltd. shows a PE of 69.03 and an EV to EBITDA of 34.71, indicating that Jeena Sikho, despite its high ratios, is still less expensive than some of its competitors. Notably, Jeena Sikho has outperformed the Sensex over the past year with a return of 102.02%, compared to the Sensex's 7.86%, but this strong performance does not justify its current valuation levels.

What is the bonus history of the Jeena Sikho?

Jeena Sikho Lifecare Ltd has announced a bonus issue of 4:5, with an ex-date of November 2, 2023. Shareholders will receive four additional shares for every five shares held as of the record date.

Jeena Sikho Lifecare Ltd recently announced a bonus issue with a ratio of 4:5, and the ex-date for this bonus is set for November 2, 2023. This means that shareholders will receive four additional shares for every five shares they hold as of the record date. If you have any more questions about the company or its financial activities, feel free to ask!

Has Jeena Sikho declared dividend?

Jeena Sikho Lifecare Ltd has declared a 41% dividend, amounting to 4.1 per share, with an ex-date of August 20, 2024. While the company has shown significant long-term returns, recent performance has been mixed, with a total return of -3.85% over the last six months.

Jeena Sikho Lifecare Ltd has declared a 41% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 41%<BR>- Amount per share: 4.1<BR>- Ex-date: 20 Aug 24<BR><BR>Dividend Yield: 0.18%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -3.85%, with a dividend return of 0%, resulting in a total return of -3.85%.<BR><BR>Over the past year, the price return was 113.33%, with a dividend return of 0.39%, leading to a total return of 113.72%.<BR><BR>In the two-year period, the price return was 743.87%, with a dividend return of 2.35%, culminating in a total return of 746.22%.<BR><BR>For the three-year period, the price return was 2643.14%, with a dividend return of 8.10%, resulting in a total return of 2651.24%.<BR><BR>In the four-year period, there was no price return and no dividend return, leading to a total return of 0.0%.<BR><BR>Over the five-year period, there was also no price return and no dividend return, resulting in a total return of 0.0%.<BR><BR>Overall, Jeena Sikho Lifecare Ltd has declared a significant dividend, but the total returns over the last several periods show a mixed performance, with substantial gains in longer time frames but some recent volatility.